

Christoph Wanner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2158712/publications.pdf>

Version: 2024-02-01

216
papers

33,431
citations

23500
58
h-index

3815
178
g-index

220
all docs

220
docs citations

220
times ranked

23501
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 135-141.	2.2	29
2	Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2022, 79, 796-806.	2.1	14
3	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology Dialysis Transplantation, 2022, 37, 1261-1269.	0.4	32
4	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	3.0	10
5	Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 38-52.	2.2	23
6	Health-Related Quality-of-Life Trajectories over Time in Older Men and Women with Advanced Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 205-214.	2.2	11
7	The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and <scp>nonâ€Asian</scp> populations of the <scp>EMPAâ€REG OUTCOME</scp> trial of patients with type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism, 2022, 24, 662-674.	2.2	15
8	Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3003-e3007.	1.8	12
9	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism, 2022, 24, 1061-1071.	2.2	15
10	Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 546-554.	2.2	7
11	From WEDA to EDTA to ERA: 60 years of supporting European Nephrology and counting. Nephrology Dialysis Transplantation, 2022, , .	0.4	0
12	Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. JAMA Internal Medicine, 2022, 182, 592.	2.6	28
13	The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 798-807.	1.4	5
14	Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study. CKJ: Clinical Kidney Journal, 2022, 15, 786-797.	1.4	4
15	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	1.0	8
16	Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. CKJ: Clinical Kidney Journal, 2022, 15, 1675-1684.	1.4	9
17	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
18	Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. CKJ: Clinical Kidney Journal, 2022, 15, 1915-1923.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1656-1663.	0.4	21
20	A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 838-851.	0.8	6
21	Treatment switch in Fabry disease- a matter of dose?. <i>Journal of Medical Genetics</i> , 2021, 58, 342-350.	1.5	9
22	Kidney function and symptom development over time in elderly patients with advanced chronic kidney disease: results of the EQUAL cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 862-870.	0.4	12
23	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
24	Characterization and implications of the initial estimated glomerular filtration rate \hat{eGFR}^{TM} upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021, 99, 750-762.	2.6	111
25	What Is the Utility of KDIGO Criteria to Identify High-Risk Populations?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 7-8.	2.1	11
26	Virtual reality: the dawn of a new ERA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1-4.	0.4	1
27	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	2.6	42
28	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.4	15
29	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.	1.4	6
30	Not only incretins for diabetic kidney disease—beneficial effects by DPP-4 inhibitors. <i>Kidney International</i> , 2021, 99, 318-322.	2.6	4
31	Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1770-1779.	1.4	7
32	Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1174-1186.	3.0	43
33	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1719-1730.	1.4	41
34	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
35	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
36	COVID-19 and the kidney: A retrospective analysis of 37 critically ill patients using machine learning. <i>PLoS ONE</i> , 2021, 16, e0251932.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <sc>EMPAâ€‘REG OUTCOME</sc> trial with a focus on Asia. Diabetes, Obesity and Metabolism, 2021, 23, 1886-1891.	2.2	18
38	High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 2375-2385.	3.0	23
39	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 2021, 144, 1265-1267.	1.6	5
40	Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury. Nephron, 2021, 145, 1-11.	0.9	4
41	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentanâ€™s Efficacy: A Post Hoc Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2731-2734.	3.0	6
42	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 104-111.	1.4	23
43	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€‘REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527.	1.4	46
44	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2313-2324.	13.9	108
45	Present and future of CONNECT: a new and compelling project of modern medicine. Nephrology Dialysis Transplantation, 2021, 37, ii1-ii3.	0.4	0
46	Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology, 2021, 12, 786706.	1.6	10
47	Mild cognitive impairment and kidney disease: clinical aspects. Nephrology Dialysis Transplantation, 2020, 35, 10-17.	0.4	38
48	Comparison of different algorithms for the assessment of cardiovascular risk after kidney transplantation by the time of entering waiting list. CKJ: Clinical Kidney Journal, 2020, 13, 150-158.	1.4	4
49	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOMEâ€™ trial. Nephrology Dialysis Transplantation, 2020, 35, 2103-2111.	0.4	20
50	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINAâ€™ trial. Diabetology International, 2020, 11, 129-141.	0.7	17
51	Status of periodontal health in German patients suffering from chronic kidney diseaseâ€™Data from the GCKD study. Journal of Clinical Periodontology, 2020, 47, 19-29.	2.3	15
52	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPAâ€‘REG OUTCOME trial. European Journal of Heart Failure, 2020, 22, 126-135.	2.9	67
53	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2020, 43, 3007-3015.	4.3	45
54	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPAâ€‘REG OUTCOME. ESC Heart Failure, 2020, 7, 3401-3407.	1.4	14

#	ARTICLE	IF	CITATIONS
55	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
56	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	6
57	Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2020, 10, 14158.	1.6	8
58	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
59	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME [®] . <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097525.	0.9	9
60	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
61	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
62	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1761-1769.	0.4	5
63	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA [®] trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1062-1073.	2.2	14
64	The authors reply. <i>Kidney International</i> , 2020, 97, 213-214.	2.6	0
65	Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype “phenotype”workgroup. <i>Journal of Medical Genetics</i> , 2020, 57, 542-551.	1.5	43
66	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1433-1444.	2.2	40
67	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	4.3	44
68	Survey about do-it-yourself closed loop systems in the treatment of diabetes in Germany. <i>PLoS ONE</i> , 2020, 15, e0243465.	1.1	7
69	Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1189-1196.	0.4	23
70	The impact of symptoms on health-related quality of life in elderly pre-dialysis patients: effect and importance in the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1707-1715.	0.4	29
71	Management of type 2 diabetes in renal disease “the twilight of the gods. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 231-233.	0.4	0
72	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease “ A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 212-223.	0.5	50

#	ARTICLE	IF	CITATIONS
73	Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 210-211.	0.5	13
74	FO055EVALUATION OF PREDICTION MODELS FOR PROGRESSION OF CHRONIC KIDNEY DISEASE TO KIDNEY FAILURE: A COMPREHENSIVE EXTERNAL VALIDATION STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
75	FC024REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
76	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 713-715.	2.1	33
77	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 222-226.	0.4	2
78	FP117SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	2
79	FP392DYNAMIC PREDICTION OF MORTALITY IN ADVANCED CKD USING TROPONIN T. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
80	FP411THE ASSOCIATION BETWEEN RENAL FUNCTION AND TROPONIN T OVER TIME IN STABLE CKD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
81	Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 20, 100493.	0.4	0
82	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1735-1745.	3.0	163
83	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019, 42, e53-e55.	4.3	27
84	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. <i>Diabetes Research and Clinical Practice</i> , 2019, 153, 30-40.	1.1	5
85	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.4	8
86	CREDENCE and DELIGHT deliver on renal benefits. <i>Nature Reviews Nephrology</i> , 2019, 15, 459-460.	4.1	3
87	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005875.	1.6	38
88	Why systematic literature reviews in Fabry disease should include all published evidence. <i>European Journal of Medical Genetics</i> , 2019, 62, 103702.	0.7	12
89	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
90	Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019, 96, 489-504.	2.6	77

#	ARTICLE	IF	CITATIONS
91	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 393, 1937-1947.	6.3	408
92	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.4	27
93	The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 19, 100454.	0.4	120
94	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019, 21, 386-388.	2.9	24
95	Left Ventricular Structure in Patients With Mild-to-Moderate CKDâ€”a Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019, 4, 267-274.	0.4	7
96	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
97	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
98	Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPAâ€”REG OUTCOME [®] trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 760-770.	1.1	61
99	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 128-139.	5.5	223
100	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 4-6.	0.4	4
101	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease â€” A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 224-235.	0.5	65
102	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	1.0	34
103	SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
104	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.4	6
105	Prospective cohort studies of beta-trace protein and mortality in haemodialysis patients and patients undergoing coronary angiography. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1984-1991.	0.4	3
106	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. <i>Kidney International</i> , 2018, 93, 1432-1441.	2.6	36
107	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME [®] trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199
108	Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes. <i>American Journal of Nephrology</i> , 2018, 47, 30-39.	1.4	5

#	ARTICLE	IF	CITATIONS
109	A new era in therapeutics for diabetic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 78-80.	4.1	5
110	Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2018, 71, 822-830.	2.1	17
111	Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1362-1372.	0.4	24
112	Rationale, design, and baseline characteristics of the CARdiovascular safety and Renal Microvascular outcomE study with LINagliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	2.7	70
113	Empagliflozin in women with type 2 diabetes and cardiovascular disease — an analysis of EMPA-REG OUTCOME®. <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49
114	Mediterranean diet as the diet of choice for patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 725-735.	0.4	114
115	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
116	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	4.3	534
117	Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 661-663.	1.3	8
118	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
119	FP593REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN DIALYSIS PATIENTS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i242-i242.	0.4	0
120	FO047REAL-WORLD EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE FOR SERUM PHOSPHORUS CONTROL IN DIALYSIS PATIENTS: AN INTERIM SUBGROUP ANALYSIS OF THE VERIFIE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i37-i38.	0.4	0
121	SP294THE EQUAL COHORT STUDY - KIDNEY FUNCTION AND SYMPTOM TRAJECTORY OVER TIME IN PREDIALYSIS ADVANCED CKD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i443-i443.	0.4	0
122	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. Hypertension, 2018, 72, 929-936.	1.3	29
123	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
124	Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2879-2889.	3.0	46
125	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018, 138, 1904-1907.	1.6	117
126	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148

#	ARTICLE	IF	CITATIONS
127	Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes—A Proposed MARE Definition. <i>Kidney International Reports</i> , 2018, 3, 1030-1038.	0.4	22
128	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i487-i487.	0.4	0
129	European expert consensus statement on therapeutic goals in Fabry disease. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 189-203.	0.5	122
130	Performance of hemodialysis with novel medium cut-off dialyzers. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw310.	0.4	140
131	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1867-1876.	3.0	157
132	Chronic kidney disease in primary care in Germany. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2017, 25, 223-230.	0.8	10
133	EMPA-REG OUTCOME: The Nephrologist's Point of View. <i>American Journal of Cardiology</i> , 2017, 120, S59-S67.	0.7	46
134	EMPA-REG OUTCOME: The Nephrologist's Point of View. <i>American Journal of Medicine</i> , 2017, 130, S63-S72.	0.6	33
135	Uromodulin in the Bloodstream: Old Wine in a New Wineskin. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1955-1957.	3.0	11
136	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
137	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
138	A Janus-headed electrolyte and "RALES" disease™. <i>ESC Heart Failure</i> , 2017, 4, 195-197.	1.4	2
139	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	18.1	558
140	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 610-621.	5.5	301
141	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 69-79.	0.9	6
142	Ecto-5' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriopathy in dialysis patients – Data from the German Calciphylaxis Registry. <i>PLoS ONE</i> , 2017, 12, e0172407.	1.1	23
143	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase Î²: data from the Fabry Registry. <i>Journal of Medical Genetics</i> , 2016, 53, 495-502.	1.5	101
144	Should we aim for oral health to improve outcomes in chronic kidney disease?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1551-1554.	0.4	4

#	ARTICLE	IF	CITATIONS
145	International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. BMC Nephrology, 2016, 17, 121.	0.8	44
146	Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet Journal of Rare Diseases, 2016, 11, 88.	1.2	29
147	Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet Journal of Rare Diseases, 2016, 11, 54.	1.2	48
148	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. CKJ: Clinical Kidney Journal, 2016, 9, 457-469.	1.4	70
149	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	13.9	2,809
150	Calculating the Rate of Senescence From Mortality Data: An Analysis of Data From the ERA-EDTA Registry. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 468-474.	1.7	5
151	The Obesity Paradox and the Role of Inflammation. Journal of the American Society of Nephrology: JASN, 2016, 27, 1270-1272.	3.0	5
152	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney International, 2016, 89, 1380-1387.	2.6	27
153	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. American Journal of Kidney Diseases, 2015, 66, 441-449.	2.1	91
154	Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Molecular Genetics and Metabolism, 2015, 114, 242-247.	0.5	51
155	Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial. PLoS ONE, 2015, 10, e0128079.	1.1	7
156	Intestinal Cholesterol Absorption, Treatment With Atorvastatin, and Cardiovascular Risk in Hemodialysis Patients. Journal of the American College of Cardiology, 2015, 65, 2291-2298.	1.2	34
157	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. American Journal of Kidney Diseases, 2015, 66, 613-620.	2.1	52
158	Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2015, 8, 248-261.	1.4	97
159	High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs. CKJ: Clinical Kidney Journal, 2015, 8, 368-373.	1.4	18
160	Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 224-231.	2.2	54
161	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrology Dialysis Transplantation, 2015, 30, 1028-1037.	0.4	81
162	Fifty years of ERA-EDTA Registry—a registry in transition. Kidney International Supplements, 2015, 5, 12-14.	4.6	10

#	ARTICLE	IF	CITATIONS
163	Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. CKJ: Clinical Kidney Journal, 2015, 8, 191-198.	1.4	49
164	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research, 2015, 12, 90-100.	0.9	333
165	Do telomeres have a higher plasticity than thought? Results from the German Chronic Kidney Disease (GCKD) study as a high-risk population. Experimental Gerontology, 2015, 72, 162-166.	1.2	17
166	Kidneys do not like excess body fat. Lancet Diabetes and Endocrinology, the, 2015, 3, 669-671.	5.5	6
167	Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study. Atherosclerosis, 2015, 242, 529-534.	0.4	27
168	Lowering cholesterol in chronic kidney disease: is it safe and effective?. European Heart Journal, 2015, 36, 2988-2995.	1.0	20
169	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney International, 2015, 88, 1411-1418.	2.6	23
170	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	13.9	8,841
171	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal, 2015, 36, ehv352.	1.0	116
172	Fabry disease and the heart. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 195-204.	2.2	62
173	HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 484-492.	3.0	37
174	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrology Dialysis Transplantation, 2015, 30, 288-293.	0.4	111
175	Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study. PLoS ONE, 2015, 10, e0122552.	1.1	18
176	Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy. PLoS ONE, 2015, 10, e0140627.	1.1	27
177	Single Nucleotide Variants in the Protein C Pathway and Mortality in Dialysis Patients. PLoS ONE, 2014, 9, e97251.	1.1	6
178	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. Circulation, 2014, 129, 999-1008.	1.6	197
179	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	2.6	91
180	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, 1956-1964.	0.4	79

#	ARTICLE	IF	CITATIONS
181	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.4	180
182	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME [®]). Cardiovascular Diabetology, 2014, 13, 102.	2.7	198
183	Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2014, 7, 227-238.	1.4	35
184	Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated With Hemodialysis: A Meta-analysis. American Journal of Kidney Diseases, 2014, 63, 84-94.	2.1	72
185	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
186	Total Nutrition Therapy Renal: A Clinical Nutrition Education Program for Nephrologists and Other Renal Health Care Professionals. , 2014, 24, 347-348.		2
187	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. Atherosclerosis, 2014, 236, 263-269.	0.4	12
188	Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv1-iv8.	0.4	65
189	Time to Revisit the Role of Renal Dietitian in the Dialysis Unit. , 2014, 24, 58-60.		14
190	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 988-996.	2.1	57
191	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney International, 2014, 86, 246-250.	2.6	84
192	KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney International, 2014, 85, 1303-1309.	2.6	452
193	Renal replacement therapy in Europe--a summary of the 2010 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2013, 6, 105-115.	1.4	14
194	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney International, 2013, 84, 1096-1107.	2.6	513
195	Renal replacement therapy in Europe--a summary of the 2009 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2012, 5, 109-119.	1.4	17
196	Factors Influencing the Decision to Start Renal Replacement Therapy: Results of a Survey Among European Nephrologists. American Journal of Kidney Diseases, 2012, 60, 940-948.	2.1	58
197	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
198	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research, 2011, 34, 209-217.	0.9	15

#	ARTICLE	IF	CITATIONS
199	Hemoglobin Cycling in Hemodialysis Patients. Nephrology Research & Reviews, 2010, 2, 1-5.	0.2	4
200	Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2220-2228.	2.2	122
201	The future of European Nephrology 'Guidelines'—a declaration of intent by European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2009, 2, 213-221.	1.4	7
202	PROGRESS IN UREMIC TOXIN RESEARCH: C-reactive Protein and Uremia. Seminars in Dialysis, 2009, 22, 438-441.	0.7	15
203	Fabry disease model: A rational approach to the management of fabry disease. Clinical Therapeutics, 2007, 29, S2-S5.	1.1	21
204	Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk. , 2007, 17, 75-78.		12
205	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. New England Journal of Medicine, 2005, 353, 238-248.	13.9	2,363
206	Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. Kidney and Blood Pressure Research, 2004, 27, 259-266.	0.9	131
207	Non-high-density lipoprotein cholesterol: A target of lipid-lowering in dialysis patients. American Journal of Kidney Diseases, 2003, 41, S72-S75.	2.1	17
208	Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney International, 2003, 63, 1934-1943.	2.6	1,379
209	Uremia-Specific Alterations in Lipid Metabolism. Blood Purification, 2002, 20, 451-453.	0.9	28
210	Lipids in end-stage renal disease. Journal of Nephrology, 2002, 15, 202-4.	0.9	4
211	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. Seminars in Dialysis, 2001, 13, 174-175.	0.7	3
212	Oxidized LDL Suppresses NF- κ B and Overcomes Protection from Apoptosis in Activated Endothelial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 456-463.	3.0	41
213	Importance of hyperlipidaemia and therapy in renal patients. Nephrology Dialysis Transplantation, 2000, 15, 92-96.	0.4	42
214	Oxygen-derived radicals stimulate renin release of isolated juxtaglomerular cells. FEBS Letters, 1994, 351, 314-316.	1.3	7
215	Lipid Disorders in Diabetic Nephropathy. , 0, , 175-192.		1
216	Dyslipidemia in Chronic Kidney Disease. , 0, , 333-344.		0